TABLE 1.
Patient characteristics.
| Number of patients | 77 | |
| Sex | ||
| Male/female | 31/46 | |
| Age (year) | ||
| Median (range) | 69 (44–84) | |
| M‐protein | ||
| IgG | 41 | 53% |
| IgA | 15 | 19% |
| BJP | 17 | 22% |
| IgD | 3 | 4% |
| Non secretory | 1 | 1% |
| ISS stage at diagnosis | ||
| Stage 1 | 18 | 23% |
| Stage 2 | 31 | 40% |
| Stage 3 | 27 | 35% |
| ND | 1 | 1% |
| RT‐PCR and fish | ||
| CCND1 | 32 | 42% |
| t(11;14) | 17 | 22% |
| 11 polysomy | 4 | 5% |
| NA | 7 | 9% |
| ND | 4 | 5% |
| FGFR3 | 17 | 22% |
| t(4;14)+ | 11 | 14% |
| t(14;16)+ | 2 | 3% |
| NA | 4 | 8% |
| c‐MAF | 16 | 21% |
| t(14;16)+ | 6 | 8% |
| NA | 9 | 12% |
| ND | 1 | 2% |
| Triple negative a | 13 | 17% |
| t(4;14)+ | 3 | 4% |
| ND | 12 | 16% |
| ASCT | ||
| +/– | 25/52 | |
| Prior therapies | ||
| Median (range) | 2 (1–6) | |
| Prior bortezomib therapy | ||
| +/– | 63 (82%)/14 | |
| Prior thalidomide therapy | ||
| +/– | 17 (22%)/60 | |
| Best response | ||
| CR | 1 | 1% |
| VGPR | 11 | 14% |
| PR | 42 | 55% |
| MR | 1 | 1% |
| SD | 18 | 23% |
| PD | 4 | 5% |
| Timepoint of sampling | ||
| Just before of Ld therapy | 77 | |
| Best response of Ld therapy | 56 | |
| Progression of disease | 49 | |
Abbreviations: CR, complete response; MR minimal response; NA, no abnormality; ND, not done; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial response.
a
CCND1‐, FGFR3‐, c‐MAF‐ negative in RT‐PCR.